ORLANDO, FLORIDA / ACCESS Newswire / October 31, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and NDT Pharmaceuticals Inc. (OTC:NDTP) on the RedChip ...
The FDA warning letters mostly went to cosmetic websites. In each case, the FDA said the companies were offering unofficial ...
Third Quarter 2025 Financial Results: Total revenue for the quarter ended September 30, 2025 was $134.2 million, up 12% from $119.8 million in the same period of 2024. This growth and operational ...
The first botulinum toxin product, onabotulinumtoxinA, was approved by the FDA in 1989. Since then, FDA has approved several ...
It is fair to say (no matter what else can be said) that the current administration is outcome- rather than process-driven. This general ...
The U.S. Food and Drug Administration issued 18 warning letters to owners of websites illegally marketing unapproved and misbranded botulinum toxin products, commonly called Botox. The agency is aware ...
The Food and Drug Administration has issued 18 warning letters to online retailers selling unapproved and misbranded Botox ...
The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...
CollaBraid is the first product the company aims to bring to market in 2026. The technology is a hybrid collagen suture — a thread-like material that surgeons use to stitch tissue together — for a ...
16h
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
Company to host conference call to discuss financial results and provide a corporate update on November 12, 2025 at 4:30 p.m. ETSCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical ...
Ironically enough, his initial downfall had nothing to do with Daraprim. Soon after he became infamous, federal prosecutors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback